M R Lemke

Summary

Affiliation: Rhine Clinic Bonn
Country: Germany

Publications

  1. ncbi Modulation of involuntary and voluntary behavior following emotional stimuli in healthy subjects
    Matthias R Lemke
    Rhine Clinic Bonn, Kaiser Karl Ring 20, 53111 Bonn, Germany
    Prog Neuropsychopharmacol Biol Psychiatry 29:69-76. 2005
  2. ncbi Depression and Parkinson's disease
    Matthias R Lemke
    Rhine Clinic Bonn, Kaiser Karl Ring 20, 53111 Bonn, Germany
    J Neurol 251:VI/24-7. 2004
  3. ncbi Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole
    Matthias R Lemke
    Center of Psychiatry and Neurology, Rhine Clinic Bonn, Germany
    J Neuropsychiatry Clin Neurosci 17:214-20. 2005
  4. ncbi Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease
    Matthias R Lemke
    Center of Psychiatry and Neurology, Rhine Clinic Bonn, Germany
    J Neurol Sci 248:266-70. 2006
  5. ncbi [Antidepressant effects of dopamine agonists. Experimental and clinical findings]
    M R Lemke
    Rheinische Kliniken Bonn, Kaiser Karl Ring 20, 53111 Bonn
    Nervenarzt 78:31-8. 2007
  6. ncbi Effect of reboxetine on depression in Parkinson's disease patients
    Matthias R Lemke
    Department of Psychiatry University of Kiel, Germany
    J Clin Psychiatry 63:300-4. 2002
  7. ncbi Suicide attempts in schizophrenia and affective disorders with relation to some specific demographical and clinical characteristics
    Daniel J Muller
    Centre for Addiction and Mental Health, Neurogenetics Section, University of Toronto, 250 College Street, M5T 1R8 Toronto, ON, Canada
    Eur Psychiatry 20:65-9. 2005
  8. ncbi Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders
    Markus Jager
    Department of Psychiatry, Ludwig Maximilians University, Nussbaumstr 7, D 80336 Munich, Germany
    Eur Arch Psychiatry Clin Neurosci 257:47-53. 2007

Collaborators

Detail Information

Publications8

  1. ncbi Modulation of involuntary and voluntary behavior following emotional stimuli in healthy subjects
    Matthias R Lemke
    Rhine Clinic Bonn, Kaiser Karl Ring 20, 53111 Bonn, Germany
    Prog Neuropsychopharmacol Biol Psychiatry 29:69-76. 2005
    ..Little is known about emotional modulation of voluntary behavior. Therefore, a paradigm was developed to study simultaneously influence of emotions on voluntary and involuntary movements...
  2. ncbi Depression and Parkinson's disease
    Matthias R Lemke
    Rhine Clinic Bonn, Kaiser Karl Ring 20, 53111 Bonn, Germany
    J Neurol 251:VI/24-7. 2004
    ..New dopamine agonists pramipexole and ropinirole appear to ameliorate depressive symptoms in PD in addition to effects on motor symptoms. There is a lack of appropriate rating scales and controlled studies regarding depression in PD...
  3. ncbi Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole
    Matthias R Lemke
    Center of Psychiatry and Neurology, Rhine Clinic Bonn, Germany
    J Neuropsychiatry Clin Neurosci 17:214-20. 2005
    ..Future studies should further investigate antianhedonic efficacy of dopamine agonists including pramipexole in depressed patients with Parkinson's disease...
  4. ncbi Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease
    Matthias R Lemke
    Center of Psychiatry and Neurology, Rhine Clinic Bonn, Germany
    J Neurol Sci 248:266-70. 2006
    ..Drop-outs due to adverse events occurred in 3.5%. Future studies should investigate specificity of anti-anhedonic and antidepressive properties of pramipexole...
  5. ncbi [Antidepressant effects of dopamine agonists. Experimental and clinical findings]
    M R Lemke
    Rheinische Kliniken Bonn, Kaiser Karl Ring 20, 53111 Bonn
    Nervenarzt 78:31-8. 2007
    ..Recently published placebo-controlled trials in small patient groups implicate that pramipexole is effective as additional treatment to mood stabilizers in I and II bipolar depression...
  6. ncbi Effect of reboxetine on depression in Parkinson's disease patients
    Matthias R Lemke
    Department of Psychiatry University of Kiel, Germany
    J Clin Psychiatry 63:300-4. 2002
    ..The efficacy of reboxetine, a novel norepinephrine reuptake inhibitor, has been shown in major depressive disorder, with specific effects on motivation and negligible effects on psychomotor and cognitive function...
  7. ncbi Suicide attempts in schizophrenia and affective disorders with relation to some specific demographical and clinical characteristics
    Daniel J Muller
    Centre for Addiction and Mental Health, Neurogenetics Section, University of Toronto, 250 College Street, M5T 1R8 Toronto, ON, Canada
    Eur Psychiatry 20:65-9. 2005
    ..Suicide attempts were associated with poor premorbid social adjustment, low age at onset, low scores on the "Global Assessment Scale" and childlessness in females...
  8. ncbi Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders
    Markus Jager
    Department of Psychiatry, Ludwig Maximilians University, Nussbaumstr 7, D 80336 Munich, Germany
    Eur Arch Psychiatry Clin Neurosci 257:47-53. 2007
    ..The aim was to investigate the hypothesis that patients with first episode schizophrenic disorders have a more favorable treatment response than those with multiple episodes...